Rejuvenate Biomed and SAS launch AI for faster age-related drug development

Rejuvenate Biomed and SAS have announced a strategic collaboration to develop an advanced platform aimed at uncovering new insights into drugs, diseases, and biological networks by systematically exploring hidden biological patterns. This cutting-edge discovery tool will be built on SAS Viya, a powerful cloud-native AI and data platform, and is poised to combine Rejuvenate Biomed’s AI-driven drug discovery capabilities with SAS’s extensive AI expertise. The goal is to enhance the efficiency and effectiveness of drug repurposing efforts, particularly for age-related diseases.

Dr. Ann Beliën, founder and CEO of Rejuvenate Biomed, emphasized the significance of this partnership for both organizations' research and development teams. She noted that by embracing this partnership and leveraging the capabilities of SAS Viya, Rejuvenate Biomed aims to de-risk and accelerate the development of its internal portfolio while enhancing its discovery platform and partnering capabilities.

The new tool promises ease of use for bioscience researchers with limited coding experience, allowing them to harness powerful analytics. Simultaneously, it will serve advanced computational biology teams by providing a foundation for developing sophisticated analytical models. The tool will employ SAS Visual Analytics to create comprehensive reports, enabling researchers to derive actionable insights from complex biomedical data.

Udo Sglavo, vice president of Applied AI and Modeling at SAS, remarked that the collaboration with Rejuvenate Biomed places SAS at the forefront of AI in biomedical research. He affirmed SAS's commitment to supporting cutting-edge applied AI and analytics through SAS Viya. According to Sglavo, Rejuvenate Biomed's endorsement of SAS Viya for the development of their unique and proprietary drug discovery engine underscores SAS's position as a premier provider of structured and scalable AI solutions that enhance data analysis efficiency and accelerate the entire drug development life cycle.

This partnership not only provides Rejuvenate Biomed with the tools to scale its drug discovery platform but also strengthens its capacity to offer third-party services and expand its drug development pipeline. By utilizing AI to uncover non-trivial and novel biological interactions, Rejuvenate Biomed aims to speed up the identification of potential therapeutic candidates and advance their development.

Rejuvenate Biomed is a clinical-stage biotechnology company focused on developing therapeutics targeting the root causes of age-related diseases. Utilizing its AI-enabled in silico CombinAge and in vivo CelegAge platforms, the company has created a pipeline of unique combination drugs addressing various age-related conditions, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative diseases. Its lead asset, RJx-01, is phase 2-ready and has demonstrated significant potential in treating sarcopenia.

Rejuvenate Biomed plans to continue generating insights for future therapeutics using its disease-agnostic drug discovery platforms. This approach is expected to drive pipeline growth and foster potential partnerships. Based in Belgium, Rejuvenate Biomed is dedicated to promoting healthy aging and advancing the science of age-related disease treatment.